Charles E Jobson, identified as a 10 percent owner of The Joint Corp (NASDAQ: JYNT), disclosed two purchases of the companys common stock in filings with the Securities and Exchange Commission. The Form 4 filing shows Jobson acquired a total of 17,478 shares across two separate transactions, executing both at an identical price of $10.00 per share.
On January 23, 2026 Jobson purchased 16,753 shares for $167,530. That transaction raised his direct holding to 1,638,424 shares. A subsequent acquisition on January 26, 2026 added 725 shares for $7,250, bringing Jobsons direct stake to 1,639,149 shares. Combined, the two transactions amount to $174,780 in insider purchases.
The price Jobson paid - $10.00 per share - is modestly above the stocks quoted trading price of $9.73 at the time referenced in the filing, and is noted to be in close alignment with InvestingPros Fair Value assessment for the company. The filing and accompanying data also indicate that The Joint Corp is a small-cap company with a market capitalization of $144.2 million and, according to InvestingPro data, holds more cash than debt on its balance sheet.
Though the company has not posted a profit over the last twelve months, it maintains a "GOOD" overall financial health score in the referenced assessment. Investors seeking additional analysis are directed to the comprehensive Pro Research Report available for JYNT and more than 1,400 other U.S. equities on InvestingPro. The Joint Corps next scheduled earnings announcement is expected on March 5, 2026.
Recent company developments accompanying Jobsons reported purchases include The Joint Corps third-quarter 2025 operating results, which showed an earnings per share (EPS) of $0.06. That EPS figure exceeded the $0.02 consensus forecast, representing a 200% surprise. Revenue for the quarter came in at $13.4 million, slightly above expectations.
Separately, The Joint Corp. has executed an Asset Purchase Agreement to sell 22 corporate-owned or managed clinics for a combined $1.5 million to three buying groups. Under the terms described, the buyers will assume business operations through Management Service Agreements until lease reassignments are completed and ownership transfers are finalized.
The company also announced the appointment of Ron Stilwell as Senior Vice President of Operations and Patient Experience. Stilwell is described as bringing three decades of experience in franchise operations and customer satisfaction to the role.
Those operational moves and leadership changes come amid what the filing and related notes describe as operational challenges and concerns about future guidance. The insider purchases by a significant stakeholder, the firms reported cash position exceeding debt, and a recent quarter that beat EPS expectations together create a factual snapshot of the companys near-term status as it approaches its next earnings date.
Summary
Charles E Jobson increased his direct holdings in The Joint Corp by 17,478 shares at $10.00 per share in late January 2026, bringing his total to 1,639,149 shares. The company registered a small-cap market capitalization of $144.2 million, reported stronger cash than debt, posted an EPS beat in Q3 2025, entered into an asset sale for 22 clinics, and named a new senior operations executive. The Joint Corp is not profitable over the trailing twelve months but retains a "GOOD" financial health score. Next earnings are expected March 5, 2026.
Key points
- Insider transactions: Jobson purchased 16,753 shares on January 23, 2026 and 725 shares on January 26, 2026, totaling 17,478 shares and $174,780 at $10.00 per share.
- Balance sheet and valuation inputs: The company has more cash than debt per InvestingPro data, a market cap of $144.2 million, and a Fair Value assessment that aligns closely with Jobsons purchase price.
- Operational and financial developments: Q3 2025 EPS of $0.06 beat the $0.02 estimate, revenue was $13.4 million, an agreement was signed to sell 22 clinics for $1.5 million, and Ron Stilwell was named SVP of Operations and Patient Experience.
Risks and uncertainties
- The Joint Corp has not been profitable over the last twelve months, indicating earnings risk for investors and potential pressure on valuation - relevant to equity and healthcare services sectors.
- The company is undergoing operational changes and faces future guidance concerns, which could affect near-term performance and franchise operations in the healthcare services sector.
- The completion of the clinic sales depends on lease reassignments and management service arrangements, creating execution risk tied to the M&A and real estate leasing processes.